Is NIVF a good stock to buy right now?

Based on our 6-factor quantitative model, NewGenIvf Group Ltd (NIVF) receives a "Hold" rating with a composite score of 43.6/100. It is ranked #544 out of 4,446 stocks. Key factor scores: Quality 41/100, Value 40/100, Momentum 50/100. The timing signal is "Bullish". This is quantitative analysis only — not investment advice.

What is the stock rating for NIVF?

NewGenIvf Group Ltd (NIVF) has a "Hold" rating and 3-star score. The composite score of 43.6 ranks it #544 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is NIVF in?

NewGenIvf Group Ltd operates in the Healthcare sector (Healthcare industry) with a market cap of $1 million. It is classified as a micro-cap stock.

Does NIVF pay a dividend?

NIVF does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is NIVF's P/E ratio?

P/E ratio data is not currently available for NIVF, which may indicate the company is not yet profitable.

How profitable is NIVF?

NIVF's quality factor score is 41/100. Gross margin: 33.6%. Margins are moderate to low, reflecting competitive market dynamics.

How is NIVF valued compared to peers?

NIVF's value factor score is 40/100 (higher = cheaper). Key multiples: , EV/EBITDA 52.3x. Trading at a premium relative to peers.

What is NIVF's debt level?

Debt data is not available for NIVF.

NIVF has a beta of 0.41, meaning it is less volatile than the market. Stability score: 24/100.

Does NIVF have high short interest?

NIVF's short interest factor score is 47/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

NIVF Stock Analysis: Top Micro-Cap Hold (Score 43.6/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
NIVF	-2.02%	-4.32%	+267.01%	+195.36%	+359.01%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.95%	-7.92%	+266.67%	+195.72%	+329.48%	-	-	-
Alpha vs Sector	-0.67%	-4.66%	+270.82%	+200.20%	+349.80%	-	-	-

Metric	NIVF	Benchmark
P/E Ratio	—	—
EV/EBITDA	52.3x	+725%
Price / Book	—

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
NIVF NewGenIvf Group Ltd	44	41	40	50	-	-	33.6%	-18.4%	-	-	$1M

Key Ratio	TTM	2024	2023	2022
Gross Margin %	0.3%	0.3%	0.3%	0.3%
Operating Margin %	-0.2%	-0.2%	0.0%	0.1%
EBITDA Margin %	0.0%	0.0%	0.1%	0.1%
Net Margin %	-0.2%	-0.2%	0.0%	0.1%
FCF Margin %	-153.1%	-153.1%	-35.7%	27.2%
ROE %	95.2%	95.2%	0.1%	1.1%
ROA %	-1.1%	-0.3%	0.1%	0.2%
ROIC %	-65.3%	-65.3%	0.9%	58.8%

Line Item	TTM	2024	2023	2022
	$5M	$5M	$5M	$6M
	$2M	$2M	$2M	$2M
Gross Margin	33.6%	33.6%	32.7%	25.9%
	—	$206K	$230K	$304K
	-$1M	-$1M	$42K	$399K
EBIT	-$1M	-$1M	$42K	$399K
EBITDA	$17K	$17K	$384K	$726K
Operating Margin	-21.4%	-21.4%	0.8%	6.7%
EBITDA Margin	0.3%	0.3%	7.5%	12.2%
	—	-$487K	$0	$208K
	-$999K	-$999K	$239K	$595K
Net Margin	-18.4%	-18.4%	4.7%	10.0%
	$-1.32	$-1.32	$0.18	$0.80
Diluted EPS	$-1.32	$-1.32	$0.18	$0.80

NewGenIvf Group Ltd (NIVF) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does NewGenIvf Group Ltd Do?

NewGenIvf Group Ltd (NIVF) is a micro-cap company in the Healthcare sector. The stock has a market capitalization of $1M, making it a notable participant in its sector. Investors researching NIVF stock will find a comprehensive, data-driven analysis below covering valuation, profitability, growth, dividends, and peer comparisons for the Healthcare space.

NewGenIvf Group Ltd (NIVF) Stock Rating — Hold (April 2026)

As of April 2026, NewGenIvf Group Ltd receives a Hold rating with a composite score of 43.6/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.NIVF ranks #544 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, NewGenIvf Group Ltd ranks #27 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NIVF Stock Price and 52-Week Range

NewGenIvf Group Ltd (NIVF) currently trades at $2.08. The 52-week high for NIVF is $6.13, which means the stock is currently trading -66.1% from its annual peak. The 52-week low is $0.26, putting the stock 705.6% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is NIVF Overvalued or Undervalued? — Valuation Analysis

NewGenIvf Group Ltd (NIVF) carries a value factor score of 40/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-sales ratio is 0.05x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, NIVF trades at 52.33x EV/EBITDA, versus 6.34x for the sector.

Overall, NIVF's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

NewGenIvf Group Ltd Profitability — ROE, Margins, and Quality Score

NewGenIvf Group Ltd (NIVF) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -111.7% versus the sector average of -33.1%.

On a margin basis, NewGenIvf Group Ltd reports gross margins of 33.6%, compared to 71.5% for the sector. The operating margin is -21.4% (sector: -66.1%). Net profit margin stands at -18.4%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NIVF Debt, Balance Sheet, and Financial Health

Balance sheet data for NIVF is evaluated through our stability factor. Total debt on the balance sheet is $3M. Cash and equivalents stand at $457,740.

NIVF has a beta of 0.41, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for NewGenIvf Group Ltd is 24/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

NewGenIvf Group Ltd Revenue and Earnings History — Quarterly Trend

In TTM 2026, NewGenIvf Group Ltd reported revenue of $5M and earnings per share (EPS) of $-1.32. Net income for the quarter was $-998,744. Gross margin was 33.6%. Operating income came in at $-1M.

In FY 2024, NewGenIvf Group Ltd reported revenue of $5M and earnings per share (EPS) of $-1.32. Net income for the quarter was $-998,744. Gross margin was 33.6%. Revenue grew 5.8% year-over-year compared to FY 2023. Operating income came in at $-1M.

In FY 2023, NewGenIvf Group Ltd reported revenue of $5M and earnings per share (EPS) of $0.18. Net income for the quarter was $238,611. Gross margin was 32.7%. Revenue grew -13.6% year-over-year compared to FY 2022. Operating income came in at $42,242.

In FY 2022, NewGenIvf Group Ltd reported revenue of $6M and earnings per share (EPS) of $0.80. Net income for the quarter was $594,514. Gross margin was 25.9%. Operating income came in at $398,705.

Over the past 4 quarters, NewGenIvf Group Ltd has experienced revenue contraction from $6M to $5M. Investors analyzing NIVF stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NIVF Dividend Yield and Income Analysis

NewGenIvf Group Ltd (NIVF) does not currently pay a dividend. This is common among smaller companies in the Healthcare industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NIVF Momentum and Technical Analysis Profile

NewGenIvf Group Ltd (NIVF) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 57/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 47/100 reflects moderate short selling activity.

NIVF vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, NewGenIvf Group Ltd (NIVF) ranks #27 out of 838 stocks based on the Blank Capital composite score. This places NIVF in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing NIVF against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NIVF vs S&P 500 (SPY) comparison to assess how NewGenIvf Group Ltd stacks up against the broader market across all factor dimensions.

NIVF Next Earnings Date

No upcoming earnings date has been announced for NewGenIvf Group Ltd (NIVF) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NIVF? — Investment Thesis Summary

NewGenIvf Group Ltd presents a balanced picture with arguments on both sides. High volatility (stability score 24/100) increases portfolio risk.

In summary, NewGenIvf Group Ltd (NIVF) earns a Hold rating with a composite score of 43.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NIVF stock.

Related Resources for NIVF Investors

Explore more research and tools: NIVF vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NIVF head-to-head with peers: NIVF vs AZN, NIVF vs SLGL, NIVF vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

NIVF: 4Q25 Earnings Preview – Doubling Down on UAE Real Estate Project

NewGen Signs MOU with Women in Web3 Hong Kong to Launch Regional Women’s Health Awareness Initiative

NewGen to Execute Up to US$2 Million Share Repurchase Program Through Benchmark

NIVF Starts Growth Phase After Transformation

NewGen Filed 2025 Annual Report on Form 20-F

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks